研究发现Parkinson和IBD的病人 缺乏关键的直肠细菌 暗示了潜在的新疗法 Study finds Parkinson's and IBD patients lack key gut bacteria, suggesting potential new therapies.

来自佛罗里达大学的一项新研究表明,患有帕金森病和炎性肠道疾病(IBD)的人的有益直肠细菌水平较低,这些细菌产生短链脂肪酸,有助于调节免疫系统。 A new study from the University of Florida reveals that people with Parkinson's disease and inflammatory bowel disease (IBD) have lower levels of beneficial gut bacteria that produce short-chain fatty acids, which help regulate the immune system. 这一调查结果表明,针对直肠微生物的疗法有可能降低Parkinson在IBD患者中的风险。 This finding suggests that therapies targeting the gut microbiome could potentially reduce the risk of Parkinson's in people with IBD. 研究人员分析了患有两种疾病的个人的肠内微生物组,并将它们与健康控制进行比较,同时注意到这两个群体都存在类似的耗竭现象。 Researchers analyzed the gut microbiomes of individuals with either disease and compared them with healthy controls, noting similar depletions in both groups.